Ventricular Tachycardia Revealing an Anderson– Fabry Disease: A Rare Case Report
Published: 2023-10-09
Page: 152-156
Issue: 2023 - Volume 5 [Issue 1]
Charif H. *
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
B. E. Ovaga
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Jama D.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
P. Mulendele
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Njie M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Haboub M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Arous S.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Bennouna E. M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Drighil A.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Habbal R.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Anderson-Fabry disease ranks as the second most common lysosomal storage disorder. It is a hereditary and rare metabolic condition resulting from a mutation in the GLA gene, responsible for encoding the lysosomal enzyme alpha-galactosidase A. This condition impacts multiple organs in the body, leading to symptoms like cerebrovascular and cardiac problems, chronic renal failure, skin lesions, peripheral neuropathy, and various other abnormalities. While the cardiac manifestations of Fabry disease are well-documented in the medical literature, occurrences where cardiac symptoms are the initial and sole clinical sign of Fabry disease are relatively infrequent. This case report highlights one such unusual situation in which persistent ventricular tachycardia serves as the first and exclusive indication of cardiac involvement in Fabry disease.
Keywords: Fabry disease, hypertrophic cardiomyopathy, ventricular tachycardia, alpha-galactosidase A, metabolic disease
How to Cite
Downloads
References
Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clinical genetics. 2005;68(1):93-5.
Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016;89:44–54.
Schiffmann R. Fabry disease. Pharmacol Ther. 2009;122:65–77.
Linhart A, Lubanda C, Palecek T, Bultas J, Karetova D, Ledvinova J, Elleder M, Aschermann M. Cardiac manifestations in Fabry disease. J Inherit Metab Dis. 2001;24:75–83.
Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, Bo¨ttcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44:340–349.
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–1235.
Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G, Barbados FJ, Mangas A, Zamorano JL. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol. 2009;132:38–44.
Pavlu L, Kocourkova L, Taborsky M, Petrkova J. Ventricular tachycardia: a presentation of Fabry disease case report. European Heart Journal-Case Reports. 2019;3(1):154.
Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, Dehaene A, Derumeaux G, Donal E, Dweck MR, Edvardsen T, Erba PA, Ernande L, Gaemperli O, Galderisi M, Grapsa J, Jacquier A, Klingel K, Lancellotti P, Neglia D, Pepe A, Perrone-Filardi P, Petersen SE, Plein S, Popescu BA, Reant P, Sade LE, Salaun E, Slart RHJA, Tribouilloy C, Zamorano J. Multimodality Imaging in Restrictive Cardiomyopathies: an EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging. 2017;18:1090–1121.
De Cobelli F, Esposito A, Belloni E, Pieroni M, Perseghin G, Chimenti C, Frustaci A, Del Maschio A. Delayed-enhanced cardiac MRI for differentiation of Fabry’s disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2009;192:W97–W102.
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–398.
Kra¨mer J, Niemann M, Sto¨rk S, Frantz S, Beer M, Ertl G, Wanner C, Weidemann F. Relationof burdenofmyocardialfibrosis to malignit ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114:895–900.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112–128.